FIELD: medicine.
SUBSTANCE: in the patient's blood plasma, catalase and glutathione reductase levels are determined, and at catalase levels of 1.137 mmol/ min/l and above and glutathione reductase levels of 4.175 μmol/min/l and above, the disease is classified as Ia clinical stage, and at catalase levels of 0 to 1.137 mmol/min/l and glutathione reductase levels of 0 to 4.175 μmol/min/l the disease is classified to the Ib-IIa clinical stage according to the international gynecological classification (FIGO).
EFFECT: method allows to reliably clarify the early stage of cervical cancer.
8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF UPDATING STAGE OF ADVANCED CERVICAL CANCER | 2015 |
|
RU2582979C1 |
| METHOD FOR DIAGNOSIS OF METASTASES TO LYMPH NODES OF SMALL PELVIS IN PATIENTS WITH RESECTABLE CERVICAL CANCER | 2020 |
|
RU2750769C2 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR UTERINE CANCER | 2012 |
|
RU2488823C1 |
| DIAGNOSTIC TECHNIQUE FOR PROGRESSIVE OVARIAN CARCINOMA | 2013 |
|
RU2536272C1 |
| METHOD FOR PREDICTION OF RECURRENCE-FREE SIRVIVAL IN CERVICAL CANCER BY BLOOD PLASMA CATALASE ACTIVITY TEST | 2012 |
|
RU2483308C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CERVICAL INTRAEPITHELIAL NEOPLASIA OF GRADE III AND MICROINVASIVE CERVICAL CANCER ASSOCIATED WITH HUMAN PAPILLOMA VIRUS | 2019 |
|
RU2735660C1 |
| METHOD FOR REDUCING STIFFNESS OF RED BLOOD CELL MEMBRANE IN PATIENTS SUFFERING FROM CERVICAL CANCER | 2013 |
|
RU2523345C1 |
| METHOD FOR PREDICTION OF RECURRENCE-FREE SURVIVAL IN CERVICAL CANCER | 2012 |
|
RU2487359C1 |
| METHOD FOR PREDICTION OF RECURRENCE-FREE SIRVIVAL IN CERVICAL CANCER BY CANCER TISSUE GLUTATHIONE REDUCTASE ACTIVITY TEST | 2012 |
|
RU2483304C1 |
| METHOD OF PREDICTION OF PROBABILITY OF CERVICAL CANCER DETECTION BASED ON ROUTINE BLOOD PARAMETERS | 2023 |
|
RU2802395C2 |
